<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33361">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01774019</url>
  </required_header>
  <id_info>
    <org_study_id>CDM00047339</org_study_id>
    <secondary_id>E7059</secondary_id>
    <nct_id>NCT01774019</nct_id>
  </id_info>
  <brief_title>Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer</brief_title>
  <official_title>Randomized Multi-Center Study Comparing No Drainage to Preoperative Biliary Drainage Using Metal Stents in Patients With Resectable Pancreatic or Periampullary Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Canada: Health Canada</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Hong Kong: Department of Health</authority>
    <authority>India: Ministry of Health</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that preoperative biliary drainage using
      self-expanding metal stents (SEMS) improves overall surgical outcomes in patients undergoing
      pancreaticoduodenectomy for treatment of pancreatic or periampullary cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of serious pre-operative, operative and post-operative adverse events to 120 days post randomization or to 30 days post surgery, whichever comes last</measure>
    <time_frame>120 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Procedure - 120 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events will be assessed in terms of rate, severity, seriousness, relatedness to stent or endoscopic or surgical procedure, impact on time of surgery, length of hospitalization and ICU stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to surgery</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Curative Intent Surgery details pertaining to intraoperative assessment of resectability, surgical resection and reconstruction techniques.</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of intraoperative blood loss and number of blood transfusions, duration of surgery</measure>
    <time_frame>At time of surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biliary obstructive symptoms assessment</measure>
    <time_frame>Baseline - 120 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of liver function test (LFT) levels as relative to baseline</measure>
    <time_frame>Week 2 - 120 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent placement success</measure>
    <time_frame>Procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Stent placement success: ability to deploy the stent in satisfactory position across the stricture (For patients who are randomized to biliary drainage with a metal stent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent removal success</measure>
    <time_frame>At time of surgery or prior to surgery if re-intervention is needed.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Stent removal success: successful SEMS removal, either en bloc at time of surgery or endoscopically prior to surgery without stent removal related SAEs  (For patients who are randomized to biliary drainage with a metal stent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number, type, reason, and timing of biliary re-interventions</measure>
    <time_frame>Baseline - 120 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital and ICU admissions</measure>
    <time_frame>Procedure - 120 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital and ICU admissions</measure>
    <time_frame>Procedure - 120 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">294</enrollment>
  <condition>Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>WallFlex™ Biliary RX Fully Covered/Uncovered Stent System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will receive a fully covered or uncovered study SEMS (self-expanding metal stent)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>None (No Pre-Operative Biliary Drainage)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this group will not receive pre-operative biliary drainage with a study SEMS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WallFlex™ Biliary RX Fully Covered/Uncovered Stent System</intervention_name>
    <arm_group_label>WallFlex™ Biliary RX Fully Covered/Uncovered Stent System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Willing and able to comply with the study procedures and provide written informed
             consent to participate in the study

          -  Diagnosis of probable pancreatic cancer, distal common bile duct (CBD)
             cholangiocarcinoma and other periampullary cancers (histology not required)

          -  Biliary obstructive symptoms or signs

          -  Bilirubin level at/above 100 umol per liter (5.8 mg/dL)

          -  Distal biliary obstruction consistent with pancreatic cancer, distal CBD
             cholangiocarcinoma or other periampullary malignancy

          -  Location of distal biliary obstruction is such that it would allow the proximal end
             of a stent to be positioned at least 2cm from the hilum

          -  Patients deemed as resectable by pancreatic protocol CT or MRI

          -  Surgical candidate per pancreatobiliary surgeon after multi-disciplinary discussion

          -  Surgery intent within 4 weeks

          -  Endoscopic and surgical treatment to be provided by same team

        Exclusion Criteria:

          -  Biliary strictures caused by confirmed benign tumors

          -  Biliary strictures caused by malignancies other than pancreatic cancer, distal CBD
             cholangiocarcinoma and other periampullary cancers

          -  Surgically altered biliary tract anatomy, not including prior cholecystectomy

          -  Neoadjuvant chemotherapy for current malignancy

          -  Palliative indication due to reasons other than surgical candidate status

          -  Previous biliary drainage by ERCP/PTC

          -  Patients for whom endoscopic techniques are contraindicated

          -  Participation in another investigational trial within 90 days

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guido Costamagna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University of the Sacred Heart</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lina Ginnetti</last_name>
    <phone>508-683-4512</phone>
    <email>lina.ginnetti@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nguyet Nguyen</last_name>
    <phone>508-683-4065</phone>
    <email>nguyet.nguyen2@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Sonson</last_name>
      <phone>+61 411 533 126</phone>
      <email>bec2153@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Michael Bourke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ULB Erasme Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mona Hammam</last_name>
      <phone>32 25 55 36 22</phone>
      <email>Mona.Hammam@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Jacques Devière, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal-Saint-Luc Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josée Gagnon</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>35806</phone_ext>
      <email>j.gagnon.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>André Roy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital, the Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Au</last_name>
      <email>kimau@surgery.cuhk.edu.hk</email>
    </contact>
    <investigator>
      <last_name>James Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hadjira Ouadfel</last_name>
      <phone>+33-610133675</phone>
      <email>hadjira.ouadfel@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Ponchon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asian Institute of Gastroenterology</name>
      <address>
        <city>Hyderabad</city>
        <zip>500 082</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suresh Gundelli</last_name>
      <email>suri.aigindia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nageshwar Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore Policlinico A. Gemelli</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Gualtieri</last_name>
      <phone>+39 (06) 35511515</phone>
      <email>c.gualtieri@eetc.it</email>
    </contact>
    <investigator>
      <last_name>Guido Costamagna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takao Itoi, MD</last_name>
      <phone>81-3-33426111</phone>
      <email>itoi@tokyo-med.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Takao Itoi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>France</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 27, 2013</lastchanged_date>
  <firstreceived_date>October 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic</keyword>
  <keyword>Periampullary Cancer</keyword>
  <keyword>Preoperative Biliary Drainage</keyword>
  <keyword>Resectable</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
